Bicalutamide, identified by its CAS number 90357-06-5, is a critical pharmaceutical compound primarily utilized in the treatment of advanced prostate cancer. As a non-steroidal pure antiandrogen, its therapeutic efficacy stems from its ability to inhibit the action of androgens, such as testosterone and dihydrotestosterone, at the androgen receptor (AR). This antagonism effectively halts the stimulation of prostate cancer cell growth, which is often androgen-dependent.

The significance of bicalutamide powder for research extends to its role as a fundamental component in the development of hormone therapies. Its high purity and consistent quality, characteristic of medical grade bicalutamide bulk drug, are essential for pharmaceutical manufacturing and preclinical studies. The compound's specific CAS number, 90357-06-5, allows for precise identification and access to detailed information regarding its properties and safety profile.

As an antineoplastic chemical medicine raw material, Bicalutamide is instrumental in creating effective treatments for hormone-sensitive prostate cancer. The continuous research into its mechanisms of action and potential combination therapies aims to improve patient outcomes and manage disease progression. Its established function as an androgen receptor inhibitor prostate cancer treatment highlights its value in clinical practice.

The strategic application of Bicalutamide, often in conjunction with LHRH analogs or surgical castration, represents a cornerstone of modern prostate cancer management. Understanding its pharmacological profile and ensuring its availability in high-quality forms are crucial for healthcare providers and researchers alike. The ongoing advancements in understanding hormonal signaling in cancer owe much to the availability and study of compounds like Bicalutamide.